Upon discovery of brain metastasis, we initiated immunotherapy combined with chemotherapy, considering PD-L1 protein immunohistochemistry: TPS=5%, CPS=20, (Table 2) and emerging data on the efficacy of combined chemoimmunotherapy in advanced NSCLC (5). This evidence concerns the gene CD274 and non-small cell lung carcinoma.